Discontinued — last reported Q4 '25
CRH Interest Paid decreased by 30.4% to $160.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 154.0%, from $63.00M to $160.00M. Over 4 years (FY 2021 to FY 2025), Interest Paid shows an upward trend with a 20.8% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
cf_interest_paid| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $85.00M | $85.00M | $85.00M | $82.25M | $82.25M | $82.25M | $82.25M | $54.00M | $147.00M | $43.00M | $174.00M | $45.00M | $171.00M | $156.00M | $227.00M | $63.00M | $188.00M | $243.00M | $230.00M | $160.00M |
| QoQ Change | — | +0.0% | +0.0% | -3.2% | +0.0% | +0.0% | +0.0% | -34.3% | +172.2% | -70.7% | +304.7% | -74.1% | +280.0% | -8.8% | +45.5% | -72.2% | +198.4% | +29.3% | -5.3% | -30.4% |
| YoY Change | — | — | — | — | -3.2% | -3.2% | -3.2% | -34.3% | +78.7% | -47.7% | +111.6% | -16.7% | +16.3% | +262.8% | +30.5% | +40.0% | +9.9% | +55.8% | +1.3% | +154.0% |